Program
rocakinogene sifuplasmid
Also written as “INO-9012”, “INO-9112” and “INO-4212 + INO-9012”.
Its studies are mostly in Glioblastoma · Carcinoma, Transitional Cell · Hepatitis B · Hemorrhagic Fever, Ebola · Breast Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Inovio Pharmaceuticals | 61 open or running | phase 2since Apr 2, 2018 | Sep 11, 2014 | Dec 31, 2027phase 2 · NCT03491683 |
| Geneos Therapeutics | 22 open or running | phase 2since Jan 27, 2020 | Jan 27, 2020 | Sep 2029phase 2 · NCT07722741 |
Also a collaborator on its studies: geneone-life-science-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2014First study: phase 1 study in NeoplasmsNew to Inovio PharmaceuticalsInovio Pharmaceuticals · NCT02241369 · 3 enrolled · United States
- Apr 21, 2015Phase 1 study in Hepatitis BInovio Pharmaceuticals · NCT02431312 · 90 enrolled · United States, Australia, Hong Kong and more
- May 28, 2015Phase 1 study in Hemorrhagic Fever, EbolaInovio Pharmaceuticals · NCT02464670 · 240 enrolled · United States
- Nov 4, 2016Phase 1 study in Breast NeoplasmsInovio Pharmaceuticals · NCT02960594 · 93 enrolled · United States
- Apr 2, 20182 phase 2 studiesInovio Pharmaceuticals · NCT03491683, NCT03502785
- Jan 27, 2020Geneos Therapeutics's first study: phase 2 study in HCCNew to Geneos TherapeuticsGeneos Therapeutics · NCT04251117 · 36 enrolled · United States, New Zealand
- Jul 20, 2026Phase 2 study in HCCGeneos Therapeutics · NCT07722741 · 90 planned · United States, New Zealand
- Oct 22, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 2 · +12 months · NCT03491683
Ahead
- Dec 31, 2027Primary completion: phase 2 study in GlioblastomaInovio Pharmaceuticals · NCT03491683
- Sep 2029Primary completion: phase 2 study in HCCGeneos Therapeutics · NCT07722741
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07722741HCC · United States, New Zealand | 2 | Recruiting | Geneos Therapeutics | Sep 2029 | 90 |
| NCT04251117HCC · United States, New Zealand | 2 | Active, not recruiting | Geneos Therapeutics | Nov 29, 2024 | 36 |
| NCT03502785Carcinoma, Transitional Cell · United States | 2 | Completed | Inovio Pharmaceuticals | May 9, 2025 | 35 |
| NCT03491683Glioblastoma · United States | 2 | Active, not recruiting | Inovio Pharmaceuticals | Dec 31, 2027 | 52 |
| NCT02960594Breast Neoplasms · United States | 1 | Completed | Inovio Pharmaceuticals | Nov 9, 2018 | 93 |
| NCT02464670Hemorrhagic Fever, Ebola · United States | 1 | Completed | Inovio Pharmaceuticals | May 24, 2018 | 240 |
| NCT02431312Hepatitis B · United States, Australia, Hong Kong and more | 1 | Completed | Inovio Pharmaceuticals | May 22, 2018 | 90 |
| NCT02241369Neoplasms · United States | 1 | Completed | Inovio Pharmaceuticals | Sep 2018 | 3 |
How it is read
Names in the registry
- “INO-9012”, 5 entries
- “INO-9112”, 1 entry
- “INO-4212 + INO-9012”, 1 entry
- “INO-4201 + INO-9012”, 1 entry
- “INO-3106, INO-9012”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 1 study
- Carcinoma, Transitional Cell, 1 study
- Hepatitis B, 1 study
- Hemorrhagic Fever, Ebola, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.